Epileptic encephalopathies are a phenotypically and genetically heterogeneous group of severe epilepsies accompanied by intellectual disability and other neurodevelopmental features 1-6 . Using next-generation sequencing, we identified four different de novo mutations in KCNA2, encoding the potassium channel K V 1.2, in six isolated patients with epileptic encephalopathy (one mutation recurred three times independently). Four individuals presented with febrile and multiple afebrile, often focal seizure types, multifocal epileptiform discharges strongly activated by sleep, mild to moderate intellectual disability, delayed speech development and sometimes ataxia. Functional studies of the two mutations associated with this phenotype showed almost complete loss of function with a dominant-negative effect. Two further individuals presented with a different and more severe epileptic encephalopathy phenotype. They carried mutations inducing a drastic gain-of-function effect leading to permanently open channels. These results establish KCNA2 as a new gene involved in human neurodevelopmental disorders through two different mechanisms, predicting either hyperexcitability or electrical silencing of K V 1.2-expressing neurons.
Many of the voltage-gated potassium channels (K V 1-K V 12) are expressed in the central nervous system (CNS), having an important role in neuronal excitability and neurotransmitter release 7 . Mutations in potassium channel-encoding genes cause different neurological diseases, including benign familial neonatal seizures (KCNQ2, encoding K V 7.2; KCNQ3, encoding K V 7.3) [8] [9] [10] , neonatal epileptic encephalopathy (KCNQ2) 11, 12 , episodic ataxia type 1 (EA1) (KCNA1, encoding K V 1.1) 13 and peripheral nerve hyperexcitability (KCNA1, KCNQ2) [13] [14] [15] . In addition, antibodies against K V 1.1 or associated proteins such as contactin-associated protein 2 (CASPR2) or leucine-rich, glioma-inactivated 1 (LGI1) cause limbic encephalitis or neuromyotonia 16 . Therefore, potassium channel genes represent interesting candidates for neurodevelopmental disorders.
To identify mutations in presumed genetic forms of epilepsy, we designed a targeted resequencing panel 17 comprising 265 known and 220 candidate genes for epilepsy (Supplementary Table 1) . Screening a pilot cohort of 33 patients, we identified mutations in known epilepsy-related genes in 16 cases 17 . We evaluated the remaining 17 cases for mutations in candidate genes (Supplementary Note), which led to the detection of a heterozygous de novo mutation in KCNA2, c.1214C>T (encoding p.Pro405Leu), affecting the highly conserved pore domain of the voltage-gated potassium channel K V 1.2 (NM_004974, CCDS827). This mutation was not present in control databases (1000 Genomes Project, Exome Variant Server (EVS), dbSNP138 or the Exome Aggregation Consortium (ExAC) database).
The affected female (patient 1) carrying this mutation had unremarkable early development until the onset of epilepsy at 17 months of age. The phenotype included febrile and afebrile alternating hemiclonic seizures and status epilepticus, reminiscent of Dravet syndrome. The electroencephalogram (EEG) showed multifocal spikes with marked activation during sleep. After seizure onset, ataxia and delay of psychomotor and language development became apparent. She had postnatal short stature, growth hormone deficiency and hypothyroidism. Seizures and ataxia responded poorly to antiepileptic drugs (topiramate, oxcarbazepine, valproic acid and bromide), including acetazolamide (known to be effective in EA1 caused by mutations in KCNA1; ref. 18 ). At last follow-up at 8 years of age, she had remained seizure free for the past 6 months without previous change of medication.
We identified further KCNA2 mutations in several parallel studies (Supplementary Fig. 1 ). First, we performed whole-exome sequencing in 86 parent-offspring trios with epileptic encephalopathy (31 with Dravet syndrome negative for mutations in SCN1A, 39 with myoclonic-atonic epilepsy (MAE) and 16 with electrical status epilepticus in slow-wave sleep (ESES)). Second, we performed panel sequencing (Supplementary Note) in 147 adults with a broad spectrum of epilepsy phenotypes associated with intellectual disability. Third, we performed whole-exome sequencing in an adult cohort of 10 independent trios with severe epilepsy and intellectual disability and whole-exome sequencing in another cohort of 12 independent, isolated index cases with early-onset ataxia and epilepsy.
We identified six additional independent cases with previously unreported heterozygous KCNA2 variants ( Table 1, Supplementary Fig. 2 and Supplementary Note). Patient 2 (initially classified as having MAE) carried the de novo mutation c.788T>C (encoding p.Ile263Thr). Patient 3 (intellectual disability with neonatal-onset focal epilepsy and cerebellar hypoplasia) carried the variant c.440G>A (encoding p.Arg147Lys), of unknown inheritance. We considered p.Arg147Lys to be a variant of unknown relevance because (i) it could not be confirmed as de novo, (ii) it was predicted to be benign using seven of nine prediction tools, (iii) a lysine occurs naturally at this position in Drosophila melanogaster and zebrafish, and (iv) the change did not show functional consequences ( Supplementary Fig. 3, Supplementary Tables 1 and 2 , and
Supplementary Note). Patient 4 (initially classified as having Dravet
De novo loss-or gain-of-function mutations in KCNA2 cause epileptic encephalopathy l e t t e r s syndrome with prominent focal seizures) and patient 5 (intellectual disability with febrile seizures, focal seizures and status epilepticus) also carried the de novo mutation encoding p.Pro405Leu ( Fig. 1c and Supplementary Fig. 2 ). Patients 1, 2, 4 and 5 eventually became seizure free between 4 and 15 years of age, whereas intellectual disability and (in patients 1 and 4) mild to moderate ataxia remained unchanged. Recurrence of the variant encoding p.Pro405Leu in three independent cases suggests a mutational hotspot: c.1214 is located in a stretch of cytosines and guanines, and the C>T mutation likely occurs owing to a methylated CpG sequence, possibly bypassing the DNA repair system and so becoming prone to this pyrimidine-pyrimidine substitution.
Patient 6 carried the de novo mutation c.894G>T (encoding p.Leu298Phe). His phenotype was different and much more severe, presenting with severe intellectual disability with gradual loss of language and motor skills, pharmacoresistant generalized tonicclonic, atypical absence and myoclonic seizures, facial dysmorphism, generalized epileptic discharges and moderate ataxia ( Table 1 and Supplementary Note). Similarly, patient 7 carrying the de novo mutation c.890G>A (encoding p.Arg297Gln) presented with a more severe phenotype consisting of moderate intellectual disability, moderate to severe ataxia and pharmacoresistant seizures.
We subsequently screened a follow-up cohort of 99 patients, comprising 47 individuals with unresolved epileptic encephalopathy, short stature and/or ataxia as well as 52 individuals with intellectual disability and idiopathic severe growth hormone deficiency, without detecting additional sequence alterations by Sanger sequencing. We excluded To validate our findings statistically and corroborate KCNA2 as a new disease-predisposing gene for epileptic encephalopathy, we calculated the probability for recurring KCNA2 mutations occurring by chance in our cohorts. Comparing the allele frequency of the 6 KCNA2 nonsynonymous variants in our validation cohorts (6/(354 × 2); excluding the first mutation encoding p.Pro405Leu detected in the discovery cohort of 33 patients) with those of missense and nonsense variants reported in the largest available control database (ExAC; 144/122,828) showed a significant enrichment of KCNA2 variants in our patient cohorts using Fisher's exact test (P = 2.6 × 10 −4 ). Further statistical evidence is provided in the Supplementary Note.
KCNA2 had not until now been associated with a human disease. However, during the review process of this manuscript, a single case report was published describing a 7-year-old boy with a KCNA2 de novo mutation encoding p.Arg297Gln presenting with ataxia and myoclonic epilepsy, similar to our patient 7 (ref. 19 ). In addition, the Pingu mouse presenting with ataxia and growth retardation carries a Kcna2 loss-of-function mutation, encoding p.Ile402Thr, in close proximity to the p.Pro405Leu substitution; Kcna2 knockout mice present with severe seizures and premature death 20, 21 .
K V 1.2 belongs to the K V 1 family of potassium channels (K V 1.1-K V 8), all members of which are expressed in the CNS. These channels consist of four subunits with six transmembrane segments (S1-S6). S4 forms the voltage sensor, and S5 and S6 form the pore region containing a selectivity filter and gating ion flow 22 (Fig. 1a) . All four KCNA2 sequence alterations detected in patients 1-7 (except the one in patient 3) were localized to highly conserved and functionally important protein regions (Fig. 1b) and were predicted to be pathogenic. p.Pro405Leu disrupts the highly conserved, K V -specific PVP motif in S6, which is thought to link the gate to the voltage sensor 23, 24 . A PVP>AVP change in K V 1.5 leads to a non-functional (d) Potassium current amplitudes were reduced for the Pro405Leu and Ile263Thr mutants in comparison to wild-type channel (top: Pro405Leu, n = 10; wild type, n = 44; bottom: Ile263Thr, n = 10; wild type, n = 34). A dominant-negative effect of the Pro405Leu and Ile263Thr mutants on wild-type K V 1.2 was seen when a constant amount of cRNA for the wild-type channel (amount 1 in b) was injected with either water or increasing amounts of cRNA for the mutant channels (top: Pro405Leu: ratio 1:1, n = 47; ratio 1:2, n = 40; ratio 1:4, n = 36; bottom: Ile263Thr: ratio 1:1, n = 34; ratio 1:2, n = 42; ratio 1:4, n = 38). Coexpression of Pro405Leu or Ile263Thr and wild-type channel led to a significant reduction in the current amplitude in comparison to expression of wild-type channel alone (indicated by an asterisk). Groups were statistically different (one-way ANOVA, P < 0.001; post-hoc Dunn's method, P < 0.05). Shown are means ± s.e.m. (e) Immunoblot analysis for lysates of Xenopus oocytes injected with equal amounts of cRNA encoding wild-type or mutant K V 1.2 (Pro405Leu, top; Ile263Thr, bottom) or for lysates of CHO cells transiently transfected with cDNA for wild-type or Pro405Leu K V 1.2 (middle). For Pro405Leu mutant channels, there was a shift from 57 kDa to ~55.5 kDa (n = 3). K V 1.2 wild-type and Ile263Thr (n = 3) channels showed similarly sized bands (57 kDa). The mock condition consisted of transfection with water.
npg l e t t e r s channel 25 . p.Ile263Thr in S3 may disrupt a hydrophobic segment proposed to focus the electric field across the cell membrane, thus enabling the S4 gating charges to translocate over a smaller distance rather than across the entire width of the membrane bilayer 26 . Furthermore, p.Ile263Thr in K V 1.2 corresponds to the p.Ile262Thr substitution in K V 1.1 causing EA1 with distal weakness 27 . Finally, p.Arg297Gln and p.Leu298Phe directly affect the S4 voltage sensor, and p.Arg297Gln has been described before to induce a negative shift in the channel activation curve 27, 28 .
We examined the functional effects of all detected sequence alterations using an automated two-microelectrode voltage-clamp Xenopus laevis oocyte testing system (Fig. 2) . We found a sigmoidal relationship between the amount of injected cRNA for wild-type K V 1.2 and the potassium current amplitude, with a strong decrease in amplitude for the eightfold cRNA amount compared to the onefold cRNA amount of wild-type channel (Fig. 2b and Supplementary Fig. 4) . We used quantitative titration of protein levels, varying the amount of injected cRNA to determine the amount to use for further experiments. For the Pro405Leu and Ile263Thr mutants, we found a dramatic reduction in current amplitude and thus a clear loss of channel function (Fig. 2c) . When either of these two mutants was coexpressed with wild-type K V 1.2 in a 1:1, 1:2 or 1:4 ratio, with a constant amount of cRNA injected for the wild-type channel, current amplitudes significantly decreased (Fig. 2d) in comparison to those obtained with similar amounts of cRNA for the wild-type channel alone (Fig. 2b) . Hence, both the Pro405Leu and Ile263Thr mutants exert a clear dominant-negative effect on wild-type K V 1.2 channels. Furthermore, Ile263Thr caused a depolarizing shift in voltage-dependent activation, and we found slight changes in inactivation for Pro405Leu (Supplementary Fig. 5) .
In contrast to the Pro405Leu and Ile263Thr mutants, both Arg297Gln and Leu298Phe induced strong gain-of-function effects. Neutralization of the second arginine in the voltage sensor in K V 1.2 through the p.Arg297Gln substitution increased current amplitudes by ninefold and shifted the voltage dependence of steady-state activation by −40 mV in comparison to the wild-type channel (Fig. 3a-c) , The gain of function for the Leu298Phe mutant was even more pronounced, with a 13-fold increase in current amplitude and a shift of −50 mV in the activation curve (Fig. 3a-c) . As a consequence of the permanently open mutant channels, the resting membrane potentials of oocytes expressing Arg297Gln or Leu298Phe channels were about 40 mV more negative than the resting potentials of oocytes expressing wild-type channel (Fig. 3d) . Both mutants exerted a dominant effect on the wild-type protein, as coinjection with cRNA for either Arg297Gln or Leu298Phe and wild-type K V 1.2 in a 0.5:0.5 ratio resulted in very similar alterations as observed with one of the mutants (1.0) alone (Fig. 3b-d) . 
e t t e r s
To examine protein production and stability, we performed SDS-PAGE analysis of total cell lysates using a monoclonal antibody to K V 1.2. Representative immunoblots showed that all mutations resulted in a protein expression level similar to that observed for the 57-kDa band corresponding to the wild-type channel (Figs. 2e and 3e) . We found a slight but reproducible shift in size for the band corresponding to Pro405Leu in both oocytes and mammalian cells (Fig. 2e, top and middle) . The steric properties of proline can disrupt secondary structure elements, which could be important for the function of the conserved PVP motif. Introduction of a leucine in this motif (LVP) could induce a structural change, resulting in altered gel migration 28 .
K V 1.2 belongs to the delayed rectifier class of potassium channels enabling efficient neuronal repolarization after an action potential. Loss-of-function mutations predict hyperexcitable neuronal membranes and repetitive neuronal firing due to impaired repolarization. This hypothesis is corroborated by the epileptic phenotype of the Kcna2 knockout mouse 21 . In stark contrast, p.Arg297Gln and p.Leu298Phe substitutions are predicted to result in permanently open channels at physiological membrane potentials and electrical silencing by membrane hyperpolarization (as we observed in oocytes). It is difficult to speculate about the pathophysiological consequences of a K V 1.2 loss-or gain-of-function mutant beyond the level of single neurons, particularly because this channel has been detected in a broad range of both excitatory and inhibitory neurons 29, 30 . Further experiments in gene-targeted mouse models could provide additional insight.
In summary, we identified de novo mutations in KCNA2 causing mild to severe epileptic encephalopathy in roughly 1.7% of the cases across our different cohorts. The phenotype associated with dominant-negative loss-of-function mutations comprised infantile or early-childhood seizure onset and frequent febrile and afebrile focal motor and dyscognitive seizures with overlap with Dravet syndrome (patients 1, 4 and 5) and MAE (patient 2). However, focal seizures are uncommon in these syndromes, and, in particular, the observed multifocal epileptiform discharges with marked activation during sleep are not described either in Dravet syndrome or MAE. All four of these patients became seizure free between 4 and 15 years of age, with this change having no apparent association with a recent change in medication. Thus, this improvement might either be due to a cumulative treatment response or simply represent spontaneous resolution ( Table 1 and Supplementary Note). Initially normal psychomotor development slowed after seizure onset, resulting in mild to moderate intellectual disability associated with mild to moderate ataxia and continuous myoclonus in some cases. By contrast, the phenotypes of patients 6 and 7, carrying mutations with dominant gain-of-function effects, were more severe in terms of epilepsy, ataxia and intellectual disability and also differed electrographically, with generalized epileptic discharges. This may suggest that different pathomechanisms underlie distinctive clinical symptoms. Clinical genetic studies and correlation with functional investigations from additional patients with further mutations are needed to confirm this genotypephenotype relationship.
URLs. dbSNP Build 138, http://www.ncbi.nlm.nih.gov/projects/SNP/; 1000 Genomes Project database, http://www.1000genomes.org/; Exome Variant Server (EVS), http://evs.gs.washington.edu/EVS/; Exome Aggregation Consortium (ExAC) database, http://exac. broadinstitute.org/; PolyPhen-2, http://genetics.bwh.harvard.edu/ pph2/; MutationTaster, http://www.mutationtaster.org/; Multiplex Amplicon Quantification (MAQ), http://www.multiplicom.com/ multiplex-amplicon-quantification-maq; Multiplex Amplicon Quantification (MAQ) Software, http://www.multiplicom.com/maq-s; ANNOVAR, http://www.openbioinformatics.org/annovar/annovar_filter. html#ljb23; GEM.app browser, https://genomics.med.miami.edu/.
METhods
Methods and any associated references are available in the online version of the paper. Accession codes. Data for the panel sequencing cohort are accessible on the GEM.app browser under the "EuroEPINOMICS CH/DK" cohort. Data for the trio exome sequencing cohorts are accessible on the GEM.app browser under the "RES EE trio sequencing" cohort. 
oNLINE METhods
Whole-exome and panel sequencing analysis. High-throughput sequencing was performed as described previously by our group for whole-exome analysis 31 and panel analysis 17 .
The panel used to screen the pilot cohort of 33 patients (including the index patient) comprised 485 known and putative epilepsy-related genes (Supplementary Table 1) . The candidates comprised genes that were suggestive of being involved in epileptogenesis on the basis of several reasons, for example, genes belong to neurotransmitter receptor families or other ion channels, genes discussed by different research groups as putatively involved in epilepsy, genes associated with seizures in animals or associated with human neurodevelopmental phenotypes, etc. The gene panel used to screen the second cohort of 147 patients was an updated version of the initial panel. To improve sequence coverage and adapt the panel for purely diagnostic purposes, we excluded a few metabolic and mitochondrial genes as well as most candidate genes and added all recently published new epileptic encephalopathy-associated genes. This panel finally contained 280 genes including 20 candidates for research settings (Supplementary Table 2 ).
Study cohorts are described in more detail in the Supplementary Note and Supplementary Figure 1 . Informed consent was obtained from the patients or their legal guardians prior to analysis. The study was approved by the ethics committees of the University of Antwerp, Belgium; University of Bern, Switzerland; and University of Kiel, Germany.
Sanger sequencing analysis and copy number variation analysis. We performed bidirectional Sanger sequencing of all three exons of KCNA2 (ENST00000485317, NM_004974) and its intron-exon boundaries using the BigDye Terminator v3.1 Cycle Sequencing kit on an ABI 3730XL DNA Analyzer (Applied Biosystems; primer sequences available upon request) in 47 patients with epileptic encephalopathy and ataxia and/or short stature as well as in 52 patients with intellectual disability and severe growth hormone deficiency.
Additionally, the genomic region containing KCNA2 was screened for CNVs by use of an in house-developed technique for multiplex amplicon quantification (MAQ). With this MAQ technique, we screened all 99 individuals of the Sanger sequencing cohort as well as all 86 individuals of the whole-exome sequencing cohort (Supplementary Fig. 1 ). This assay comprises multiplex PCR amplification of fluorescently labeled target and reference amplicons followed by fragment analysis on the ABI 3730 DNA Analyzer 32 . The comparison of normalized peak areas for the test individual and the average of seven control individuals yields target amplicon doses indicating the copy number of the target amplicon (using the in house-developed MAQ software). The multiplex PCR reaction consisted of three test amplicons located in the genomic region of KCNA2 and three reference amplicons located on different chromosomes (the primer mix is available upon request).
Pathogenicity predictions. For prediction of the pathogenicity of nonsynonymous variants, we used the ANNOVAR 33 table_annovar.pl script together with the LJB23 database (dbNSFP) 34 from June 2013 comprising prediction scores from SIFT, PolyPhen-2 (HDIV and HVAR), LRT, MutationTaster, MutationAssessor, FATHMM, MetaSVM and MetaLR. Scores were used as given on the ANNOVAR webpage. Three additional conservation scores (GERP+, phyloP and SiPhy) were used to determine the conservation of a genomic position (more details are provided in Supplementary Table 2 ).
Testing the enrichment of pathogenic variants. To test the enrichment of probably damaging nonsynonymous KCNA2 variants in our data, we used the ExAC database as a control data set. It comprises data from 61,486 individuals from various exome sequencing projects, including data for control cohorts, but also data from studies on neurological disorders such as schizophrenia and bipolar disorder. We extracted all 64 nonsynonymous (missense and nonsense) variants for KCNA2 from ExAC (November 2014). Some of these occurred in more than one individual yielding all together 144 alleles with variation in KCNA2 out of a total of 122,828 alleles in the ExAC database. Significant enrichment of nonsynonymous variants was then tested determining the difference in allele counts for our data set and the ExAC data set using Fisher's exact test.
Probability assessment of de novo mutation events. We first obtained an estimate for the single-nucleotide mutation rate in the KCNA2 gene. This rate equals the product of the average de novo mutation rate in humans of 1.2 × 10 −8 mutations per nucleotide per generation 35 and the length of the largest coding sequence of KCNA2 (CCDS database, 827.1) of 1,500 bp, yielding 1.8 × 10 −5 mutations per generation. The probability of observing a de novo mutation in KCNA2 in k out of n parent-offspring trios then simply follows a binomial distribution with a success probability equaling the gene-based mutation rate, binomial(n, k, 1.8 × 10 −5 ) (Supplementary Note).
Functional investigations. Mutagenesis and RNA preparation. Site-directed mutagenesis was performed to engineer the mutations into human KCNA2 cDNA using QuikChange (Agilent Technologies; primer sequences are available upon request). Mutant cDNA was fully resequenced before being used in experiments to confirm the introduced mutation and exclude the presence of any additional sequence alterations. cRNA was prepared using the SP6 mMessage kit from Ambion. cDNA for human K V 1.2 in the pcDNA3.1 vector was kindly provided by S. Grissmer (Ulm University).
Electrophysiology. Xenopus oocytes were obtained from the Institute of Physiology I, Tübingen, Germany. Preparation of the oocytes was performed as described previously 12 . Experiments were approved by the local Animal Care and Use Committee (Regierungspräsidium Tübingen, Tübingen, Germany). Oocytes were treated with collagenase (1 mg/ml type CLS II collagenase, Biochrom) in OR-2 solution (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 and 5 mM HEPES, pH 7.5), washed three times and stored at 16 °C in Barth solution (88 mM NaCl, 2.4 mM NaHCO 3 , 1 mM KCl, 0.33 mM Ca(NO 3 ) 2 , 0.41 mM CaCl 2 , 0.82 mM MgSO 4 and 5 mM Tris-HCl, pH 7.4 with NaOH) supplemented with 50 µg/ml gentamicin (Biochrom). We injected 50 nl of cRNA encoding wild-type or mutated K V 1.2 subunits (1 µg/µl, which corresponds to the cRNA amount of 1.0) into oocytes using the Roboocyte2 (Multi Channel Systems), and oocytes were stored for 2 d (at 17 °C) before the experiment. Current amplitudes for wild-type and mutant channels recorded on the same day were normalized to the mean value with a cRNA amount of 1.0 for wild-type K V 1.2 recorded on that day to pool the normalized data from different experiments together.
Automated two-electrode voltage-clamp. Potassium currents in oocytes were recorded at room temperature (20-22 °C) using Roboocyte2 (Multi Channel Systems). For two-electrode voltage-clamp (TEVC) recordings, oocytes were impaled with two glass electrodes with a resistance of 0.4-1 MΩ containing a solution of 1 M KCl and 1.5 M potassium acetate and clamped at a holding potential of −80 mV. Oocytes were perfused with an ND96 bath solution containing 93.5 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 2 mM MgCl 2 and 5 mM HEPES (pH 7.6). Currents were sampled at 5 kHz.
Voltage clamp protocols and data analysis. The membrane was depolarized to various test potentials from a holding potential of −80 mV to record potassium currents. The activation curve was derived from the current-voltage relationship that was obtained by measuring the peak current at various step depolarizations from the holding potential of −80 mV (10-mV increment, depolarized to +70 mV). The following Boltzmann function was fitted to the obtained data points Protein blot analysis. For protein blotting, injected Xenopus oocytes were lysed in a buffer containing 20 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.5% Triton X-100 and 10% glycerol with cOmplete protease inhibitors (Roche). In addition, for the mutation encoding p.Pro405Leu, CHO cells were transfected with 10 µg/µl DNA using Mirus TransIT-LT1 reagent. CHO cells were lysed in a buffer containing 2 M Tris (pH 7.5), 3 M NaCl, 0.2 M EDTA, 0.2 M EGTA, 0.25 M sodium pyrophosphate, 0.1 M β-glycerophosphate, 0.1 M sodium orthovanadate, 1 M DTT, 0.1 M 1% Triton X-100 and 25× cOmplete solution (Roche). After measuring protein concentrations (BCA Systems, Thermo Fisher Scientific), 15-20 µg of protein was separated by SDS-PAGE on 8% polyacrylamide gels. Proteins were transferred onto polyvinylidene fluoride (PVDF) membranes (PALL Corporation) and protein blotting was performed using a mouse antibody to K V 1.2 (NeuroMab clone K14/16). Water-injected oocytes and untransfected and water-transfected CHO cells were used as controls.
Data and statistical analysis. Sample size was estimated by using GraphPad StatMate software. TEVC recordings were analyzed using Roboocyte 2+ (Multi Channel Systems) and Clampfit (pClamp, Axon Instruments), Origin 6.1 (Origin-Lab Corporation) and Excel (Microsoft) software. Data were tested for a normal distribution using SigmaPlot12 (Systat software). For statistical evaluation, one-way ANOVA with Dunnett's post-hoc test (normally distributed data) or one-way ANOVA on ranks with Dunn's post-hoc test (data not normally distributed) was used to compare multiple groups, with one-way ANOVA testing the overall difference between groups and post-hoc tests examining the difference between specific groups. For unpaired data sets, Student's t test (normally distributed, unpaired data sets) or Mann-Whitney rank-sum test (data not normally distributed) was used. All data are shown as means ± s.e.m. For all statistical tests, significance with respect to the control is indicated in the figures using the following symbols: *P < 0.05, **P < 0.01, ***P < 0.001.
